info@bivictrix.com
August 11th, 2025
BiVictriX Therapeutics Strengthens Board with US-Facing Appointment
Read more
June 26th, 2025
BiVictriX Therapeutics – BVX002 Data Update
Read more
June 11th, 2025
Business Update
Read more
September 10th, 2024
Last Day of Dealings
Read more
September 09th, 2024
BiVictriX Reports Positive Initial In Vivo Data from BVX002 Solid Tumour Programme
Read more
August 12th, 2024
Proposed voluntary cancellation of admission of Ordinary Shares to trading on AIM Proposed re-registration as a Private Limited Company Adoption of New Articles And Notice of General Meeting
Read more
August 01st, 2024
BiVictriX Interim results for the six months ended 30 June 2024
Read more
June 13th, 2024
Compelling Safety Profile of BVX001 in Pre-Clinical Models Supports Progression to Clinic
Read more
June 06th, 2024
BiVictriX Announces Innovate UK Grant Award to Accelerate Solid Tumour Targeting ADC Pipeline
Read more
May 31st, 2024
BiVictriX Final Results For The Year Ended 31 December 2023
Read more
April 17th, 2024
BiVictriX Announces FDA Orphan Drug Designation and completion of FDA INTERACT meeting for BVX001 in the treatment of Acute Myeloid Leukaemia
Read more
January 04th, 2024
BiVictriX Hosts Inaugural Roundtable Discussion with Globally Renowned Experts to Appraise BVX001 as an Emerging, Differentiated Therapy for the Treatment of AML
Read more
Load more
Quick links
Head office
Mereside
Alderley Park
Alderley Edge
Cheshire, UK
SK10 4TG info@bivictrix.com
Copyright: BiVictriX Therapeutics Limited 2026.

All Rights Reserved. Design & Development By Online Web Studio